Liquidity
Weak0.51
How the figure is assessed
Current assets divided by current liabilities. Below 1.0 is weak, 1.0–1.5 needs attention and 1.5 or more is strong.
Org. no. 964 911 444 · Private limited company (AS) · Active · Industriveien 33, 1337, SANDVIKA · BÆRUM · 72.100 – Research and experimental development on natural sciences and engineering
ALGIPHARMA AS is a private limited company (as) registered in SANDVIKA since 1992. The organisation number is 964 911 444. The register lists 5 employees. The latest submitted annual accounts are for 2025.
Source: The Brønnøysund Register Centre · Last updated 19 November 2026 at 04:48
Quick overview
Based on the latest submitted annual accounts (2025) and registry data.
0.51
Current assets divided by current liabilities. Below 1.0 is weak, 1.0–1.5 needs attention and 1.5 or more is strong.
-23,016.6 %
Operating profit divided by operating revenue. Below 0% is weak, 0–10% needs attention and 10% or more is strong.
84.8 %
Equity divided by assets. Below 10% is weak, 10–30% needs attention and 30% or more is strong.
Calculated by us
Based on status, solvency, liquidity, profitability, trend and how recent the accounts are. Public register data only.
This is an indicative assessment, not a credit rating. It does not replace your own due diligence before entering into an agreement.
Proffi+
Calculating …
Indicative model estimate based on public accounting figures and typical industry multiples. Not an appraisal, a valuation or investment advice.
Development
Revenue and profit
RevenueResult
Development
Solvency and profitability (%)
SolidityProfitability
Registry data
Addresses
Not registered
Industry
Research and experimental development on natural sciences and engineering(main industry)
N Professional, scientific and technical activities › 72 Scientific research and development › 72.1 Research and experimental development on natural sciences and engineering › 72.10 Research and experimental development on natural sciences and engineering
See the industry: largest companies and key figures →Omfatter: Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk; forskning og utvikling innenfor naturvitenskap, forskning og utvikling innenfor teknikk og teknologi, forskning og utvikling innenfor medisin, helse og veterinærvitenskap, forskning og utvikling innenfor bioteknologi, forskning og utvikling innenfor jordbruk, skogbruk og fiske, tverrfaglig forskning og utvikling, hovedsakelig innenfor naturvitenskap og teknikk. Omfatter også: DNA-sekvensering når formålet er generell forskning på biologiske prosesser. Ekskluderer: DNA-sekvensering for å utelukke eller kurere en spesifikk sykdom grupperes under 86.91 Medisinske laboratorietjenester og bildediagnostikk.
Institutional sector code: Private aksjeselskaper mv. (2100)
Forskning og kommersialisering av forskningsprosjekter og forskningsresultater knyttet til alginater og annen bioteknologi og virksomhet i tilknytning til detter, herunder deltakelse i andre virksomheter gjennom aksjeeie eller på annen måte.
Registry status
Experiences
Loading reviews …
You must sign in with a verified email to write a review.
Financial overview
Fiscal year 2025 · Amounts in NOK
Data basis
3 stored years
0.51
Current assets divided by current liabilities. Below 1.0 is weak, 1.0–1.5 needs attention and 1.5 or more is strong.
-23,016.6 %
Operating profit divided by operating revenue. Below 0% is weak, 0–10% needs attention and 10% or more is strong.
84.8 %
Equity divided by assets. Below 10% is weak, 10–30% needs attention and 30% or more is strong.
Only reported amounts from the Register of Company Accounts
| Accounting item | 2025 | 2024 | 2023 | Development |
|---|---|---|---|---|
| Operating revenue | 29,219 | 5,738 | 85,940 | |
| Operating profit | -6,725,210 | -6,858,426 | -5,843,676 | |
| Profit before tax | -8,676,949 | -8,962,504 | -9,831,509 | |
| Net result | -8,676,949 | -8,962,504 | -9,715,740 | |
| Total assets | 232,824,118 | 207,325,830 | 188,878,585 | |
| Equity | 197,468,543 | 176,145,487 | 128,587,961 | |
| Liabilities | 35,355,574 | 31,180,343 | 60,290,624 |
Graphical analysis
Amounts in NOK
Calculated by us, in percent
Balance sheet in NOK
Register of Company Accounts
Period 2025-01-01 to 2025-12-31. Currency NOK. Audited annual accounts.
| Total operating revenue | 29,219 NOK |
|---|---|
| Total operating expenses | 6,754,429 NOK |
| Operating profit | -6,725,210 NOK |
| Total financial income | 1,603,144 NOK |
| Total financial expenses | 3,554,883 NOK |
| Net financial items | -1,951,739 NOK |
| Profit before tax | -8,676,949 NOK |
| Net result | -8,676,949 NOK |
| Total fixed assets | 225,097,166 NOK |
|---|---|
| Total current assets | 7,726,952 NOK |
| Total assets | 232,824,118 NOK |
| Paid-in equity | 197,468,543 NOK |
|---|---|
| Total equity | 197,468,543 NOK |
| Current liabilities | 15,170,925 NOK |
| Long-term liabilities | 20,184,649 NOK |
| Total debt | 35,355,574 NOK |
| Total equity and liabilities | 232,824,118 NOK |
Register of Company Accounts
Period 2024-01-01 to 2024-12-31. Currency NOK. Audited annual accounts.
| Total operating revenue | 5,738 NOK |
|---|---|
| Total operating expenses | 6,864,163 NOK |
| Operating profit | -6,858,426 NOK |
| Total financial income | 1,714,483 NOK |
| Total financial expenses | 3,818,561 NOK |
| Net financial items | -2,104,079 NOK |
| Profit before tax | -8,962,504 NOK |
| Net result | -8,962,504 NOK |
| Total fixed assets | 201,536,517 NOK |
|---|---|
| Total current assets | 5,789,313 NOK |
| Total assets | 207,325,830 NOK |
| Paid-in equity | 176,145,487 NOK |
|---|---|
| Total equity | 176,145,487 NOK |
| Current liabilities | 16,356,455 NOK |
| Long-term liabilities | 14,823,888 NOK |
| Total debt | 31,180,343 NOK |
| Total equity and liabilities | 207,325,830 NOK |
Register of Company Accounts
Period 2023-01-01 to 2023-12-31. Currency NOK. Audited annual accounts.
| Total operating revenue | 85,940 NOK |
|---|---|
| Total operating expenses | 5,929,616 NOK |
| Operating profit | -5,843,676 NOK |
| Total financial income | 1,868,780 NOK |
| Total financial expenses | 5,856,614 NOK |
| Net financial items | -3,987,833 NOK |
| Profit before tax | -9,831,509 NOK |
| Net result | -9,715,740 NOK |
| Total fixed assets | 181,567,841 NOK |
|---|---|
| Total current assets | 7,310,744 NOK |
| Total assets | 188,878,585 NOK |
| Paid-in equity | 128,587,961 NOK |
|---|---|
| Total equity | 128,587,961 NOK |
| Current liabilities | 12,624,763 NOK |
| Long-term liabilities | 47,665,861 NOK |
| Total debt | 60,290,624 NOK |
| Total equity and liabilities | 188,878,585 NOK |
Source: Register of Company Accounts, Brønnøysund Register Centre. Figures are shown as submitted, and historical years are never overwritten by newer submissions.
Calculated by us
| Key figures | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue growthChange in total operating revenue from the previous fiscal year. | 409.2 % | -93.3 % | – |
| Operating marginOperating profit divided by total operating revenue. | -23,016.6 % | -119,526.4 % | -6,799.7 % |
| Profit marginOrdinary profit before tax divided by total operating revenue. | -29,696.3 % | -156,195.6 % | -11,440 % |
| Equity ratioTotal equity divided by total assets. | 84.8 % | 85 % | 68.1 % |
| Current ratioTotal current assets divided by total current liabilities. | 0.51 | 0.35 | 0.58 |
| Debt ratioTotal liabilities divided by total equity. | 0.18 | 0.18 | 0.47 |
| Return on assetsOrdinary profit before tax plus financial expenses, divided by total assets. | -2.2 % | -2.5 % | -2.1 % |
| Return on equityNet profit divided by total equity. | -4.4 % | -5.1 % | -7.6 % |
About the calculation
The key figures are calculated by us (formula version v1) from public accounts in the Register of Company Accounts. A figure is only calculated when all input values exist and the denominator is not zero. The figures are not a credit assessment.
Registry data
Source: The Brønnøysund Register Centre. We only show name and role as published by the register – never date of birth or private address.
Structure
Overview
ALGIPHARMA AS
SANDVIKA · 5 employees
Registry data
| Name | Org. no. | Place | Employees |
|---|---|---|---|
| ALGIPHARMA ASResearch and experimental development on natural sciences and engineering | 990 367 566 | SANDVIKA | 5 |
This has not been registered yet. We never show made-up information.
Services and products
The company has not added any services yet.
Public approvals
Not in the Norwegian Building Authority's central approval register.
Public contracts
No notices found in TED where the company is a supplier or contracting authority.
Registered changes
We show changes from the Brønnøysund Register Centre's change log from the next registered change.
Documents
Certificates of registration and other documents require a separate agreement with a document provider.
Transparency
Company information
Brønnøysund Register Centre · Public register
Last retrieved 19 November 2026 at 04:48
Open official sourceRoles
Brønnøysund Register Centre · Public register
Last retrieved 19 November 2026 at 04:48
Open official sourceAccounts and key figures
Register of Company Accounts · Public register
Last retrieved 19 November 2026 at 04:48
Open official sourceAddress (verified)
Norwegian Mapping Authority – Geonorge address API · Public register
Last retrieved 19 November 2026 at 04:48
Open official sourceCentral approval
Norwegian Building Authority (DiBK) · No approval found
Last retrieved 19 November 2026 at 04:48
Open official sourceIndustry standard (SN2007)
Statistics Norway – KLASS · Official standard
Last retrieved 19 November 2026 at 04:48
Open official sourcePublic registry data is updated periodically and cannot be changed by the company. Calculated figures are marked “Calculated by us”.
Report an errorSource
Public registry fields on this page come from the Central Coordinating Register and cannot be changed by the company. Self-reported content is marked separately.
Read about the data sourcesTalk to Proffi
Leave your contact details and an adviser will explain how segmentation, company profiles and supplier search can support your business.